Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine
Agilent Technologies (NYSE: A) has announced a nonexclusive collaboration with Lunit (KRX:328130.KQ) to develop AI-powered companion diagnostic solutions. The partnership combines Lunit's artificial intelligence expertise with Agilent's tissue-based diagnostic capabilities to enhance biomarker testing accuracy.
The collaboration will initially focus on developing AI-powered assays for research and clinical trials, integrating Lunit's AI algorithms with Agilent's state-of-the-art assays. The joint solutions aim to support pharmaceutical companies in companion diagnostic product development, potentially accelerating the development of biomarker-driven therapies and improving patient treatment precision.
Agilent Technologies (NYSE: A) ha annunciato una collaborazione non esclusiva con Lunit (KRX:328130.KQ) per sviluppare soluzioni diagnostiche companion basate sull’IA. La partnership unisce l’expertise di Lunit nell’intelligenza artificiale alle capacità diagnostiche su tessuti di Agilent per migliorare l’accuratezza dei test sui biomarcatori.
La collaborazione, inizialmente, si concentrerà sullo sviluppo di saggi guidati dall’IA per la ricerca e le sperimentazioni cliniche, integrando gli algoritmi IA di Lunit con i saggi all’avanguardia di Agilent. Le soluzioni congiunte mirano a supportare le aziende farmaceutiche nello sviluppo di prodotti diagnostici companion, potenzialmente accelerando lo sviluppo di terapie guidate dai biomarcatori e migliorando la precisione del trattamento dei pazienti.
Agilent Technologies (NYSE: A) ha anunciado una colaboración no exclusiva con Lunit (KRX:328130.KQ) para desarrollar soluciones de diagnóstico acompañante impulsadas por IA. La asociación combina la experiencia en inteligencia artificial de Lunit con las capacidades de diagnóstico basadas en tejidos de Agilent para mejorar la precisión de las pruebas de biomarcadores.
La colaboración, en una primera etapa, se centrará en desarrollar pruebas impulsadas por IA para la investigación y ensayos clínicos, integrando los algoritmos de IA de Lunit con los avanzados estándares de ensayo de Agilent. Las soluciones conjuntas tienen como objetivo apoyar a las compañías farmacéuticas en el desarrollo de productos de diagnóstico acompañante, con el potencial de acelerar el desarrollo de terapias basadas en biomarcadores y mejorar la precisión de tratamiento para los pacientes.
Agilent Technologies (NYSE: A)가 Lunit (KRX:328130.KQ)와 비독점 협력을 발표하여 AI 기반의 동반 진단 솔루션을 개발합니다. 이 파트너십은 Lunit의 인공지능 전문지식과 Agilent의 조직 기반 진단 역량을 결합해 바이오마커 검사 정확도를 향상시키고자 합니다.
협력은 우선 연구 및 임상시험을 위한 AI 기반 분석법 개발에 중점을 두고, Lunit의 AI 알고리즘을 Agilent의 최첨단 분석법과 통합합니다. 공동 솔루션은 제약회사가 동반 진단 제품 개발을 지원하도록 하여, 바이오마커 기반 치료제 개발을 가속화하고 환자 치료의 정밀성을 높일 수 있습니다.
Agilent Technologies (NYSE: A) a annoncé une collaboration non exclusive avec Lunit (KRX:328130.KQ) pour développer des solutions de diagnostic compagnon alimentées par l’IA. Le partenariat combine l’expertise en IA de Lunit et les capacités de diagnostic basées sur les tissus d’Agilent afin d’améliorer la précision des tests de biomarqueurs.
La collaboration se concentrera, dans un premier temps, sur le développement de savoir-faire basés sur l’IA pour la recherche et les essais cliniques, en intégrant les algorithmes d’IA de Lunit aux essais de pointe d’Agilent. Les solutions conjointes visent à aider les entreprises pharmaceutiques dans le développement de produits de diagnostic compagnon, avec le potentiel d’accélérer le développement de thérapies guidées par les biomarqueurs et d’améliorer la précision du traitement des patients.
Agilent Technologies (NYSE: A) hat eine nicht exklusive Zusammenarbeit mit Lunit (KRX:328130.KQ) angekündigt, um KI-gesteuerte Companion-Diagnostik-Lösungen zu entwickeln. Die Partnerschaft kombiniert Lunits KI-Expertise mit Agilents gewebebasierten Diagnostikfähigkeiten, um die Genauigkeit von Biomarker-Tests zu verbessern.
Die Zusammenarbeit wird sich zunächst auf die Entwicklung KI-gestützter Assays für Forschung und klinische Studien konzentrieren und Lunits KI-Algorithmen mit Agilents modernen Tests integrieren. Die gemeinsamen Lösungen zielen darauf ab, Pharmaunternehmen bei der Entwicklung von Companion-Diagnostic-Produkten zu unterstützen, potenziell die Entwicklung biomarker-gesteuerter Therapien zu beschleunigen und die Behandlungspräzision für Patienten zu verbessern.
Agilent Technologies (NYSE: A) أعلنت عن تعاون غير حصري مع Lunit (KRX:328130.KQ) لتطوير حلول تشخيص مرافقة مدعومة بالذكاء الاصطناعي. تمزج الشراكة خبرة Lunit في الذكاء الاصطناعي مع قدرات Agilent التشخيصية المعتمدة على الأنسجة لتعزيز دقة اختبارات المؤشرات الحيوية.
سيتركز التعاون في البداية على تطوير اختبارات مدفوعة بالذكاء الاصطناعي للبحث والتجارب السريرية، مع دمج خوارزميات الذكاء الاصطناعي الخاصة بـ Lunit مع اختبارات Agilent المتقدمة. تهدف الحلول المشتركة إلى دعم شركات الأدوية في تطوير منتجات التشخيص المرافق، مع إمكانية تسريع تطوير العلاجات المعتمدة على المؤشرات الحيوية وتحسين دقة علاج المرضى.
Agilent Technologies (NYSE: A) 已宣布与 Lunit (KRX:328130.KQ) 建立非排他性合作，共同开发由人工智能驱动的伴随诊断解决方案。此次合作将 Lunit 的人工智能专长与 Agilent 基于组织的诊断能力结合起来，以提升生物标志物检测的准确性。
初期，合作将聚焦于为研究和临床试验开发 AI 驱动的分析方法，整合 Lunit 的 AI 算法与 Agilent 的先进分析方法。联合解决方案旨在帮助制药公司开发伴随诊断产品，可能加速基于生物标志物的治疗药物开发，并提高对患者治疗的精准性。
- Strategic partnership combines Agilent's diagnostic leadership with Lunit's AI expertise
- Potential to accelerate biomarker-driven therapy development
- Access to Lunit's established presence in over 7,000 medical institutions across 65 countries
- Enhancement of diagnostic accuracy through AI integration
- Nonexclusive nature of the collaboration may limit competitive advantages
- Initial focus limited to research and clinical trials phase
Insights
Agilent's partnership with Lunit combines diagnostic expertise with AI to advance precision medicine and potentially accelerate revenue growth.
Agilent Technologies has entered a strategic nonexclusive collaboration with Lunit to develop AI-powered companion diagnostic (CDx) solutions that could significantly strengthen its position in the precision medicine market. This partnership intelligently combines Agilent's established leadership in tissue-based diagnostics with Lunit's specialized AI algorithms designed for cancer detection and analysis.
The collaboration addresses a critical market need: while biomarker testing forms the foundation of precision oncology, current processes remain heavily dependent on manual interpretation, creating inefficiencies and potential inconsistencies. By integrating AI capabilities into diagnostic workflows, the partnership aims to enhance the accuracy, precision, and speed of biomarker testing – three metrics that directly impact pharmaceutical development timelines and treatment efficacy.
For Agilent specifically, this collaboration represents a meaningful competitive enhancement to its Clinical Diagnostics Division. The company gains access to Lunit's AI expertise without exclusive commitments, allowing flexibility in future partnerships while immediately strengthening its offering to pharmaceutical partners developing biomarker-driven therapies.
The initial focus on research and clinical trial applications creates a clear commercialization pathway, as successful validation in these settings typically precedes broader clinical adoption. This methodical approach aligns with regulatory requirements while potentially accelerating Agilent's revenue growth in the expanding companion diagnostics market, which is projected to grow substantially as precision medicine becomes increasingly central to cancer treatment protocols.
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Under this agreement, Lunit and Agilent will develop advanced AI-powered companion diagnostic tools designed to enhance the accuracy of diagnosis and the measurement of therapeutic efficacy. The initial focus will be on leveraging Lunit's AI algorithms with Agilent's state-of-the-art assays to evaluate biomarkers critical for the development of new pharmaceutical therapies.
The joint solutions will support pharmaceutical companies in companion diagnostic (CDx) product development, improving the precision and accuracy of biomarker testing, and ultimately benefiting patients with more tailored treatment options.
"Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation," said Brandon Suh, CEO of Lunit. "By combining Agilent's global leadership in tissue-based diagnostics with Lunit's proven AI algorithms, we can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence - ultimately ensuring patients receive the right treatment at the right time."
"Agilent is committed to bringing cutting-edge diagnostic solutions to our pharmaceutical partners and ultimately to patients, and this collaboration with Lunit further strengthens our ability to offer the most advanced companion diagnostic solutions available today," said Nina Green, vice-president and general manager of Agilent's Clinical Diagnostics Division at Agilent. "Through this collaboration with Lunit, we aim to deliver next-generation diagnostic tools that enable the advancement of precision medicine worldwide."
The collaboration will initially focus on the co-development of AI-powered assays for use in research and clinical trials. This agreement marks a significant step forward for both companies as they seek to redefine the role of artificial intelligence in precision oncology and translational medicine.
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 7,000 medical institutions in more than 65 countries, while Lunit SCOPE is used in research partnerships with global pharma giants focused on biomarker development and companion diagnostics. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/lunit-and-agilent-technologies-announce-collaboration-to-enhance-development-of-companion-diagnostic-solutions-powered-with-ai-for-precision-medicine-302562617.html
SOURCE Lunit
FAQ
What is the purpose of Agilent and Lunit's AI collaboration announced in September 2025?
How will the Agilent-Lunit partnership benefit patients?
What is Lunit's current market presence in medical diagnostics?
What is the initial focus of the Agilent-Lunit collaboration?
How does this collaboration affect Agilent's (NYSE: A) diagnostic capabilities?
